Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Open Access
- 30 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-11
- https://doi.org/10.1038/s41467-020-17526-5
Abstract
Frameshift insertion/deletions (fs-indels) are an infrequent but highly immunogenic mutation subtype. Although fs-indels are degraded through the nonsense-mediated decay (NMD) pathway, we hypothesise that some fs-indels escape degradation and elicit anti-tumor immune responses. Using allele-specific expression analysis, expressed fs-indels are enriched in genomic positions predicted to escape NMD, and associated with higher protein expression, consistent with degradation escape (NMD-escape). Across four independent melanoma cohorts, NMD-escape mutations are significantly associated with clinical-benefit to checkpoint inhibitor (CPI) therapy (Pmeta = 0.0039). NMD-escape mutations are additionally found to associate with clinical-benefit in the low-TMB setting. Furthermore, in an adoptive cell therapy treated melanoma cohort, NMD-escape mutation count is the most significant biomarker associated with clinical-benefit. Analysis of functional T cell reactivity screens from personalized vaccine studies shows direct evidence of fs-indel derived neoantigens eliciting immune response, particularly those with highly elongated neo open reading frames. NMD-escape fs-indels represent an attractive target for biomarker optimisation and immunotherapy design.Funding Information
- Cancer Research UK (TRACERx)
- RCUK | Medical Research Council (MR/P014712/1)
This publication has 40 references indexed in Scilit:
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014
- TCPA: a resource for cancer functional proteomics dataNature Methods, 2013
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsNature Medicine, 2013
- Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translationProceedings of the National Academy of Sciences of the United States of America, 2011
- Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayNature, 2010
- A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell CarcinomaJournal of Translational Medicine, 2010
- Probability-based protein identification by searching sequence databases using mass spectrometry dataElectrophoresis, 1999
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986